Transcatheter mitral valve intervention: an emerging treatment for mitral regurgitation

Markham, R.; Kyranis, S.; Aroney, N.; Lau, Kendy; Poon, K.; Scalia, G.; Walters, D.

doi:10.1111/imj.13750

Cited by 4 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, total mitral valve replacement is being supplanted when possible by mitral valve sparing procedures, including the use of various mitral valve clip devices. Pathology associated with these devices and procedures have been described [6,10,128,[139][140][141][142][143][144].…”

Section: Valvular Heart Diseasementioning

confidence: 99%

Pathobiology of cardiovascular diseases: an update

Buja

Ottaviani

Mitchell

2019

Cardiovascular Pathology

View full text Add to dashboard Cite

This article introduces the Second Special Issue of Cardiovascular Pathology (CVP), the official journal of the Society for Cardiovascular Pathology (SCVP). This CVP Special Issue showcases a series of commemorative review articles in celebration of the 25 th anniversary of CVP originally published in 2016, and now compiled into a virtual collection with online access for the cardiovascular pathology community. This overview also provides updates on the major categories of cardiovascular diseases from the perspective of cardiovascular pathologists, highlighting publications from CVP, as well as additional important review articles and clinicopathologic references.

show abstract

Section: Valvular Heart Diseasementioning

confidence: 99%

Pathobiology of cardiovascular diseases: an update

Buja

Ottaviani

Mitchell

2019

Cardiovascular Pathology

View full text Add to dashboard Cite

show abstract

“…This is a safer way for patients because transcatheter therapy is mini invasive and avoids risks accompanied with open heart surgery. These techniques are developed for interventions on many parts of mitral valve apparatus (24). Regulation of blood pressure (BP) is under control of sympathetic nervous system (25).…”

Section: Sympathovagal Dynamic Balance -Functionmentioning

confidence: 99%

Sympathetic nervous system and cardiovascular risk in mitral valve prolapse

Olexova

Mestanik

Jurko

et al. 2019

Acta Medica Martiniana

View full text Add to dashboard Cite

Mitral valve prolapse (MVP) represents a frequent cardiovascular condition associated with increased cardiovascular risk, which may have progressive course and become malignant. Dysregulation of autonomic nervous system - especially sympathetic overdrive – is one of the factors considered to play a key role in its aetiology and development. There is a growing evidence of a large impact of sympathetic system on the development of MVP. Exaggerated sympathetic activity may lead to morphologic changes in valves tissue such as thickening and redundancy. Nowadays, few investigative methods are known for evaluation of the regulatory state of sympathetic nervous system, which could be, theoretically, used to identify the subjects with sympathetic overactivity associated with an increased cardiovascular risk. Electrodermal activity or blood pressure variability represent promising non-invasive methods for evaluation of the regulatory outputs of sympathetic nervous system. There is a possibility to extend a set of investigative methods in MVP and include the monitoring of sympathetic activity in the assessment of cardiovascular risk. This article summarizes knowledge about pathogenesis, diagnostic and therapeutical approaches of MVP, and brings some novel insights on the parameters of autonomic nervous regulation, which haven’t yet been used in cardiovascular risk assessment in MVP.

show abstract

“…Mitral valve regurgitation (MR) is the second most frequent valvular dysfunction in Europe, after aortic stenosis [1,2]. It is estimated that around 10% of population aged over 75 have moderate to severe MR [3]. It can be caused by structural abnormality of one or more components of the mitral valve (primary MR), or by the distortion of the mitral valve apparatus caused by left ventricle (LV) and/or left atrium (LA) remodelling (secondary MR) [4].…”

Section: Introductionmentioning

confidence: 99%

“…Severe MR is a major source of morbidity and mortality worldwide and a frequent cause of heart failure, being associated with unfavourable prognosis when remains untreated [ 5 ]. Despite surgery is the treatment of choice for patients with severe MR, approximately 50% of patients are not eligible for surgery due to comorbidities [ 3 , 6 ]. In the recent years, transcatheter mitral valve implantation (TMVI) is emerging as an effective alternative to surgery in high-risk surgical candidates [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…Despite surgery is the treatment of choice for patients with severe MR, approximately 50% of patients are not eligible for surgery due to comorbidities [ 3 , 6 ]. In the recent years, transcatheter mitral valve implantation (TMVI) is emerging as an effective alternative to surgery in high-risk surgical candidates [ 3 ]. TMVI revolutionised the management of mitral valve repair/replacement percutaneously based on MR aetiology and patients’ anatomical and clinical characteristics [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic changes of mitral valve annulus geometry at preprocedural CT: relationship with functional classes of regurgitation

et al. 2021

View full text Add to dashboard Cite

Background We investigated mitral valve annular geometry changes during the cardiac cycle in patients with severe mitral regurgitation (MR) who underwent cardiac computed tomography angiography (CCTA) prior to percutaneous mitral valve replacement or annuloplasty. Methods Fifty-one patients with severe MR and high surgical risk (Carpentier classification: 3 type I, 16 type II, 16 type IIIa, 16 type IIIb) underwent multiphase electrocardiographically gated (0–90%) CCTA, using a second generation dual-source CT scanner, as pre-procedural planning. Twenty-one patients without MR served as controls. The mitral valve annulus was segmented every 10% step of the R-R interval, according to the D-shaped segmentation model, and differences among groups were analysed by t-test or ANOVA. Results Mitral annular area and diameters were larger in MR patients compared to controls, particularly in type II. Mitral annular area varied in MR patients throughout the cardiac cycle (mean ± standard deviation of maximum and minimum area 15.6 ± 3.9 cm2versus 13.0 ± 3.5 cm2, respectively; p = 0.001), with greater difference between annular areas versus controls (2.59 ± 1.61 cm2 and 1.98 ± 0.6 cm2, p < 0.001). The largest dimension was found in systolic phases (20–40%) in most of MR patients (n = 27, 53%), independent of Carpentier type (I: n = 1, 33%; II: n = 10, 63%; IIIa: n = 8, 50%; IIIb: n = 8, 50%), and in protodiastolic phases (n = 14, 67%) for the control group. Conclusions In severe MR, mitral annular area varied significantly throughout the cardiac cycle, with a tendency towards larger dimensions in systole.

show abstract

Transcatheter mitral valve intervention: an emerging treatment for mitral regurgitation

Cited by 4 publications

References 40 publications

Pathobiology of cardiovascular diseases: an update

Pathobiology of cardiovascular diseases: an update

Sympathetic nervous system and cardiovascular risk in mitral valve prolapse

Dynamic changes of mitral valve annulus geometry at preprocedural CT: relationship with functional classes of regurgitation

Contact Info

Product

Resources

About